Member Info for David1951c

https://www.g7uk.org/g7-health-ministers-meeting-communique-oxford-4-june-2021/
AMR is extensively covered in paras 24 - 31 so is seen as a major threat. Destiny have well advanced novel products and surely will qualify for grant assistance and accelerated development and approval foreseen would also speed up the delivery through Phase 3 trials and products reaching commercial launches. Much could happen in next 18 months.

Hard to understand why people are selling just before an update. With so much going on (see Feb update) I remain optimistic and believe a sustained rise is possible if ONC issue more regular news as well as a comprehensive quarterly update. The potential is significant and I did not expect a drop to 200p but this is AIM with crazy pricing methodologies and practices.

Good news of progress. Phase 3 clinical trials due to start in 2022 are on a sound footing and collaboration news will hopefully come in H2.

Good to hit on first drill. Question to be answered with more drilling will this be viable commercially?

Based on the previous RNSs there should be news by 31 May. Interim results RNS in Feb said "Evidence of sustainable growth with a commercial pipeline of over 100 opportunities (up 50% since October 2020) of which 19 are potential contracts with a value of £10.8 million from follow-on contracts with existing customers or proposals for new customers. We expect to announce the signing of a number of these before the end of this financial year."
Any downward SP drift is always disappointing but the SP has come a long way on the strength of ONC's impressive breadth and pipeline. A good time to buy more for those with funds available.

Hard to have faith in this company (one of my worst investment decisions) when everything takes until next year. I did top up to have a lower average on the slim chance revenue will come before another fund raise is required but it will be close run. I suspect more money will be raised to fund efforts in Spain. The only reason I stay in is the low Mcap and a big rise is possible if the developments are successful. Goodness knows what management and staff do to fill their days as the two main projects are minority and cannot require so much effort. I hope not to sound bitter but I am disappointed. Thankfully this is only a minor part of my portfolio but it is regular reminder of not believing in optimistic statements from a company with a track record of non or delayed delivery!

Impossible to justify any future Mcap based on usual fundamentals such as revenue and profit. My hope is at least £280m by end of 2021 based on the impressive range of what ONC have under way - reading 15 Feb update again shows the potential and with Roche / Genentech collaborations announced since and more news to come this month there could be more interest to push SP along. Fund raise in March means the resources to continue the various workstreams for the forseeable future. The unknown factor is whether there will be a take over from a major like Roche who work with ONC and know them well.
SP fluctuations are frustrating and a relatively small sell volume of £60k has pushed the Mcap down by more than £10m which doesn't make sense except AIM pricing methodologies are nuts anyway. Importantly SP is some way above March placing @180p.

It is only right that the company is not allowed to fail. It should be kept in operation and future profits used to meet the amounts due to creditors over a period of years. Dividends should not be allowed until reasonable creditors' claims have been met. If the company fails creditors will receive less than would otherwise be possible and administration would cost millions that would reduce creditor payments even more. Hope the judge will analyse the business plan and key assumptions to validate the projected future profits and possible future creditor payments. A win win solution is possible in spite of the useless FCA.

SP moves on low volumes a hallmark of AIM. Whether MMs move the market I don't know but it is frustrating. What is frustrating is the low SP and not much can move that without concrete developments with some real numbers on revenue and moving to profitability. Latest RNS is weak and revenue impact is not given. Not sure about 10p as I will sell at 2p to move funds to opportunities missed by staying invested here. Company claim to be a global leader in their field but leadership in dropping the SP seems closer to the reality we face. Hoping 2021 results will be released soon. I am sorry to say these may not be as good as hoped for but hope to be proved wrong. On AIM good news comes quickly but bad news takes time!

FY ends on 31 May and news is expected before then. With the emphasis on cancer in today's news, one of the news items could be Early CDT lung blood test and additional NHS contracts. Already approved by NICE so a wider roll out would be simple and quick.

March quarter RNS also referred to preparing a JORC for Big One but typically no timelines given. In latest RNS reference to Board being optimistic of transformational developments is not that strong an endorsement. How about being confident? I am optimistic the SP will rise to day but not confident it will sustain the rise.
Potential is there but when will anything material happen and will it be before cash runs low? If only these companies could see the situation through investors eyes!

Should add the whole sector is down - PHE, ITM, IES, Ceres, IShares Clean Energy. Not sure of the underlying reasons and believe the potential is excellent.

There are a number of reasons:
1. More sells than buys because PIs are impatient and move their money to other opportunities
2. Top slicing even now. I sold some recently but kept 4m on free carry
3. Lack of progress; with so many deals in the pipeline why is there not more regular news of completions
4. Nothing said about Wood reports and that caused me to sell some.

EQT could have a lot of potential and Mcap of £117m is a fraction of what it might be one day. They need to get a move on, close more projects and increase their revenue.

Keyboard playing up! "buy" more.
Futura (FUM) is even more volatile having peaked at 79p on 22 March then dropped below 50p and now up almost 30% today. What a roller coaster ride! With these volumes there is a lot more trading and Destiny is a more stable share.

It is the nature of AIM with SP rising on good news and then drifting backwards until something else happens. It just has to be accepted - look at others for a similar pattern e.g. Future, Oncimmune and Angle. If you believe in a company then be prepared to back you judgement especially when there will probably be more transformational developments within 12 months such as with Destiny. They have two major Phase 3 trials in 2022 and others potentially. Their novel products will assist with MRSA and infections an area of growing concern. The company is fully funded to end of 2022 but may well bring in partners to accelerate developments and in additional areas. Mcap today is around £100m and if they are successful the potential is significant. Nothing is guaranteed but the company is de-risked with excellent P2 data. At some point there may be a takeover but no-one really knows. I am OK about SP fluctuation even with the frustration of seeing paper profit dwindle in the short term. I will by more if SP dips below 140p.

It is also important to note that it will be used to treat other COPD lung conditions not just Covid. It is safe and is most effective where it is needed most - in patients with severe breathlessness. SNG should offer their services to the Health Service in India.

News could come soon but at the latest by end of FY on 31 May. Worth recapping the main points of update in 15 February RNS.
- ImmunoInsights pipeline of over 100 opportunities for which capacity has been put in place.
- Infectious Diseases Panel in place in February with a panel available to commercial organisations in H2. In advanced discussions with several global biopharmas.
- Early CDT with negotiations for a substantial NHS Trust which could conclude soon; partner distribution with Biodesix in USA; discussions in other major markets including Brazil;
- funding for large cancer control project with 65,000 people

will give a great opportunity to get a further update and ask questions. Even if information is already available it would be good to hear management talking about chances of success and anticipated drilling times. The depth and ground don't look too challenging.

SP rises at 8am on good news and then falls back with many sells as has happened in last 38 minutes. Hopefully it won't lose all the gains but what we are not seeing is any concrete information of revenue these deals may bring. It is impossible for me to know if this is a mega company changing deal or much more modest. I have held shares for three years so nicely in profit but I am not a trader and sometimes the traders seem to win. Unfortunately there are no extra benefits for LTHs. If that were possible, it would be a big advantage.

AIM show little regard to shareholders in general and some companies show almost contempt to theirs. It is wrong and companies should be compelled to give quarterly updates to shareholders as they do in some jurisdictions. As a shareholder of 7Dig for a couple of years I am not as long suffering as many but as shareholders we in theory own the company and ought to be better treated. The last trading update was in December so another is over due and results are due soon too. Normally a company is able to give some information or indications before audited results. 7 Dig have not and this suggests an update may not be pretty. Another feature on AIM is good news comes early and bad news is delayed. I hope to be wring but I am also tempted to sell even at a loss. Having averaged down it is not such a hit but unwelcome. I'd rather invest in a company that respects its shareholders.